Circulating IL-8 levels in heart failure patients with and without metabolic syndrome

Clinica Chimica Acta

Volumn 405, Issue 1-2, 2009, Pages 139-142

  Shin, Min Jeong ^a   Lee, Kyung Hye ^b   Chung, Ji Hyung ^b   Park, Yoo Kyoung ^c   Choi, Mi Kyung ^d   Oh, Jaewon ^e   Choi, Ji Won ^e,f   Lee, Sang Hak ^f   Chung, Namsik ^e,f   Kang, Seok Min ^e,f  

^a Korea University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kyung Hee University   (South Korea)

^d Keimyung University   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Yonsei University   (South Korea)

Author keywords

C reactive protein; Heart failure; Interleukin 8; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; INTERLEUKIN 8; LIPOPROTEIN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL;

BLOOD GLUCOSE; C-REACTIVE PROTEIN; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-8; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 67349204319     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.04.020     Document Type: Article

References (30)

1. Kannel W.B. Incidence and epidemiology of heart failure. Heart Fail Rev 5 (2000) 167-173
2. Sliwa K., Damasceno A., and Mayosi B.M. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 112 (2005) 3577-3583
3. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107 (2003) 1486-1491
4. Anker S.D., and von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 90 (2004) 464-470
5. Braunwald E. Biomarkers in heart failure. N Engl J Med 358 (2008) 2148-2159
6. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108 (2003) 2317-2322
7. Bahrami H., Bluemke D.A., Kronmal R., et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 51 (2008) 1775-1783
8. Butler J., Rodondi N., Zhu Y., et al. Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 47 (2006) 1595-1602
9. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States Adults. Circulation 110 (2004) 1245-1250
10. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 285 (2001) 2486-2497
11. Steering Committee of the WHO Western Pacific Region, IASO & IOTF. The Asia-Pacific perspective: redefining obesity and its treatment, Australia (2000)
12. Anand I.S., Latini R., Florea V.G., et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112 (2005) 1428-1434
13. Alonso-Martínez J.L., Llorente-Diez B., Echegaray-Agara M., Olaz-Preciado F., Urbieta-Echezarreta M., and González-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4 (2002) 331-336
14. Ridker P., Buring J., Cook N., and Rifai N. C reactive protein, the metabolic syndrome and risk of incident cardiovascular events: an 8 year follow-up of 14719 initially healthy American women. Circulation 107 (2003) 391-397
15. Herder C., Haastert B., Müller-Scholze S., et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54 (2005) S11-17
16. Bruun J.M., Verdich C., Toubro S., Astrup A., and Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol 148 (2003) 535-542
17. Yu R., Kim C.S., Kawada T., et al. Involvement of leukotactin-1, a novel CC chemokine, in human atherosclerosis. Atherosclerosis 174 (2004) 35-42
18. Zozulinska D., Majchrzak A., Sobieska M., Wiktorowicz K., and Wierusz-Wysocka B. Serum interleukin-8 level is increased in diabetic patients. Diabetologia 42 (1999) 117-118
19. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M., and Ferrer J. Prognostic value of interleukin-8 as a predictor of heart failure in patients with myocardial infarction and percutaneous intervention. Int J Cardiol 111 (2006) 158-160
20. Haffner S., and Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 108 (2003) 1541-1545
21. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14 (2003) 137-145
22. Gerhardt C.C., Romero I.A., Cancello R., Camoin L., and Strosberg A.D. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 175 (2001) 81-92
23. Bruun J.M., Lihn A.S., Madan A.K., et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab 286 (2004) E8-E13
24. Yudkin J.S., Stehouwer C.D., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
25. Devaraj S., Kumaresan P.R., and Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 36 (2004) 405-410
26. Seta Y., Shan K., Bozkurt B., Oral H., and Mann D.L. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2 (1996) 243-249
27. Kim H.Y., Kang Y.J., Song I.H., Choi H.C., and Kim H.S. Upregulation of Interleukin-8/CXCL8 in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats. Hypertens Res 3 (2008) 515-523
28. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
29. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
30. Ingelsson E., Arnlöv J., Sundström J., Zethelius B., Vessby B., and Lind L. Novel metabolic risk factors for heart failure. J Am Coll Cardiol 46 (2005) 2054-2060